Surrozen becomes clinical-stage with Phase 1 starts for SZN-1326 and SZN-043

Surrozen, Inc./DE

2022-Q2 EPS reported -$0.63

Initiated Phase 1 trial for SZN-1326 (ulcerative colitis) in May 2022 and for SZN-043 (alcoholic hepatitis) in June 2022.
Presented preclinical data for SZN-413 (diabetic retinopathy) at ARVO and for other pipeline programs at Digestive Disease Week.
Q2 2022 financial results reported but specific figures (revenue, EPS, net loss) not included in provided exhibit text.
Company noted no treatment-related adverse effects in preclinical toxicology studies for both lead candidates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.